POM-V Prescription Required

Pergocoat 2 mg Film-coated Tablets for Horses

Active ingredient: Pergolide

Form

Tablet

Species

Horses

Manufacturer

Alfasan Nederland B.V.

VMD MA No.

36408/3028

What it's used for

Symptomatic treatment of clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) (Equine Cushing’s Disease).

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Pergolide

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Pergocoat 2 mg Film-coated Tablets for Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Symptomatic treatment of clinical signs associated with Pituitary Pars Intermedia
Dysfunction (PPID) (Equine Cushing’s Disease).

Do not use in horses with known hypersensitivity to pergolide mesilate or other ergot
derivatives or to any of the excipients.
Do not use in horses less than 2 years of age.

Horses:
Rare
(1 to 10 animals / 10,000
animals treated):
Inappetence, transient anorexia and lethargy,
mild central nervous system signs (e.g. mild
depression and mild ataxia), diarrhoea and colic.
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Sweating.

Revised: January 2025
AN: 00986/2024
Reporting adverse events is important. It allows continuous safety monitoring of a
product. If you notice any side effects, even those not already listed in this package
leaflet, or you think that the medicine has not worked, please contact, in the first
instance, your veterinarian. You can also report any adverse events to <the
marketing authorisation holder> <the local representative of the marketing
authorisation holder> using the contact details at the end of this leaflet, or via your
national reporting system <{national system details}.

Appropriate endocrinologic laboratory tests should be conducted as well as
evaluation of clinical signs in order to establish a diagnosis of PPID.

Revised: January 2025
AN: 00986/2024

i). Special precautions for use in animals
As the majority of cases of PPID are diagnosed in aged horses, other
pathological processes are frequently present. For monitoring and frequency
of testing, see section 4.9.
ii). Special precautions to be taken by the person administering the veterinary
medicinal product to animals
This veterinary medicinal product may cause eye irritation, an irritating smell,
or headache after dividing the tablets. Avoid contact with the eyes and
inhalation when handling the tablets. Minimise exposure risks when dividing
or dissolving tablets, e.g. tablets should not be crushed.
In case of contact with skin, wash exposed skin with water. In the event of
eye exposure, flush the affected eye immediately with water and seek
medical advice. For nasal irritation, move to fresh air and seek for medical
attention if breathing difficulty develops.
This product may cause hypersensitivity (allergy) reactions. People with
known hypersensitivity to pergolide or other ergot derivatives should avoid
contact with the veterinary medicinal product.
This product may cause adverse effects due to decreased prolactin levels,
which poses a particular risk to pregnant and lactating women. Pregnant or
lactating women should avoid dermal contact or hand-to-mouth contact by
wearing gloves when administering the product.
Accidental ingestion, especially by children, may cause vomiting, dizziness,
tiredness, or low blood pressure. To avoid accidental ingestion, carefully
keep the product out of reach and sight of children. Tablet parts should be
returned to the open blister space. Blisters should be inserted back into the
outer packaging and kept in a safe place. In case of accidental ingestion,
seek medical advice immediately and show the package leaflet or the label to
the physician.
Do not eat, drink or smoke when using this product. Wash hands after use.
iii). Other precautions
Not applicable

Use with caution in case the veterinary medicinal product is co-administered with
other drugs known to affect protein binding.
Do not administer concurrently with dopamine antagonists, such as neuroleptics
(phenothiazines - e.g. acepromazine), domperidone, or metoclopramide, as these
agents may reduce the effectiveness of pergolide.

This veterinary medicinal product does not require any special storage conditions.

mg/kg body weight per day. Use only according to the benefit/ risk assessment by the
responsible veterinarian.
Lactation:
The use is not recommended in lactating horses, in which the safety of this veterinary
medicinal product has not been demonstrated. In mice, reduced body weights and
survival rates in the progeny were attributed to the

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.